Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies

The prognosis of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is poor. Chimeric antigen receptor (CAR) T-cell therapy has been approved for R/R DLBCL after 2 prior lines of therapy based on data from single-arm phase 2 trials, with complete responses (CRs) in 40%...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood Adv
Glavni autori: Sermer, David, Batlevi, Connie, Palomba, M. Lia, Shah, Gunjan, Lin, Richard J., Perales, Miguel-Angel, Scordo, Michael, Dahi, Parastoo, Pennisi, Martina, Afuye, Aishat, Silverberg, Mari Lynne, Ho, Caleb, Flynn, Jessica, Devlin, Sean, Caron, Philip, Hamilton, Audrey, Hamlin, Paul, Horwitz, Steven, Joffe, Erel, Kumar, Anita, Matasar, Matthew, Noy, Ariela, Owens, Colette, Moskowitz, Alison, Straus, David, von Keudell, Gottfried, Rodriguez-Rivera, Ildefonso, Falchi, Lorenzo, Zelenetz, Andrew, Yahalom, Joachim, Younes, Anas, Sauter, Craig
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2020
Teme:
Clinical Trials and Observations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7556134/
https://ncbi.nlm.nih.gov/pubmed/33002134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002118
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items